 High-dose medroxyprogesterone acetate versus estramustine therapy-resistant prostatic cancer randomised study series patients metastatic prostatic cancer first-line hormonal treatment high-dose medroxyprogesterone acetate MPA mg i.m daily days mg weekly patients mg os patients treatment side effects evaluable MPA-treated patients evaluable estramustine-treated patients Progression-free survival short groups significant difference year patients significant difference treatments cumulative observed survival rates SPCG criteria remissions weeks MPA-treated patients estramustine-treated patients difference significant cross-over patients MPA group remission estramustine group response rate subjective objective response criteria MPA side effects